Search Results - "Hubner, R A"

Second-line chemotherapy in advanced biliary cancer: a systematic review by Lamarca, A., Hubner, R.A., David Ryder, W., Valle, J.W.

“…The randomized NCRN phase III ABC-02 trial provided level-A evidence for first-line chemotherapy with cisplatin and gemcitabine combination in advanced biliary…”
Get full text

Folate and colorectal cancer prevention by Hubner, R A, Houlston, R S

“…Anti-folate chemotherapy agents such as methotrexate and fluorouracil reduce proliferation of neoplastic cells by inhibiting DNA synthesis. Paradoxically…”
Get full text

Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours by Monaghan, P.J., Lamarca, A., Valle, J.W., Hubner, R.A., Mansoor, W., Trainer, P.J., Darby, D.

“…Summary Objective Chromogranin A (CgA) and B (CgB) are markers for monitoring disease status in patients with gastroenteropancreatic neuroendocrine tumours…”
Get full text

Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma by HUBNER, R. A, LIU, J.-F, SELLICK, G. S, LOGAN, R. F. A, HOULSTON, R. S, MUIR, K. R

“…The effects of polymorphisms in genes coding for key folate metabolism enzymes such as thymidylate synthetase (TS) on colorectal neoplasia risk are likely to…”
Get full text

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma by Abou-Alfa, G.K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H.Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W.P., Chen, Z., Hubner, R.A., Meyer, T., Sun, W., Harding, J.J., Hollywood, E.M., Ma, J., Wan, P.J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., Chen, L.-T.

“…Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting…”
Get full text

Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery by Slagter, A.E, Ryder, D, Chakrabarty, B, Lamarca, A, Hubner, R.A, Mansoor, W, O’Reilly, D.A, Fulford, P.E, Klümpen, H.J, Valle, J.W, McNamara, M.G

“…Abstract Aim Surgery is the only modality of cure in patients diagnosed with neuroendocrine tumours (NETs). The aim of this study was to identify prognostic…”
Get full text

Influence of co-morbidity on renal function assessment by Cockcroft–Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy by Hubner, R.A, Goldstein, R, Mitchell, S, Jones, A, Ashley, S, O’Brien, M.E.R, Popat, S

“…Abstract Background Creatinine clearance (CrCl) estimation by Cockcroft–Gault calculation (CG) often replaces measurement of glomerular filtration rate (GFR)…”
Get full text

Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC) by Lamarca, A., Frizziero, M., Barriuso, J., McNamara, M. G., Hubner, R. A., Valle, J. W.

“…Background Platinum-etoposide (PE) chemotherapy (CH) is a globally established combination for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC);…”
Get full text

Outcomes in patients ≥ 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy by Lewis, A. R., Cipriano, C., Wang, X., Ward, R., Fitzpatrick, A., Scott, A. R. M., Rashed, A., Raja, H., Lamarca, A., Hubner, R. A., Valle, J. W., McNamara, M. G.

“…Older patients are underrepresented in oncological clinical trials. The incidence of hepatopancreaticobiliary (HPB) malignancies is higher in older patients,…”
Get full text

Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit by King, J, Palmer, D.H, Johnson, P, Ross, P, Hubner, R.A, Sumpter, K, Darby, S, Braconi, C, Iwuji, C, Swinson, D, Collins, P, Patel, K, Nobes, J, Muazzam, I, Blesing, C, Kirkwood, A, Nash, S, Meyer, T

“…Abstract Aims Sorafenib is the current standard treatment for advanced hepatocellular carcinoma. We carried out a national audit of UK patients treated with…”
Get full text

Reply to the letter to the editor ‘Second-line chemotherapy in advanced biliary cancer: the present now will later be past’ by Vivaldi et al by Lamarca, A., Hubner, R.A., Ryder, W.D., Valle, J.W.

Get full text

Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib by Lamarca, A., Abdel-Rahman, O., Salu, I., McNamara, M. G., Valle, J. W., Hubner, R. A.

“…Background Identification of patients with advanced HCC-deriving preferential benefit from sorafenib is desirable, and treatment-related adverse events are…”
Get full text

Bisphosphonates' use in metastatic bone disease by Hubner, R A, Houston, S J

“…Bisphosphonates already have an established role in the management of the skeletal complications of metastatic bone disease. The development of new, highly…”
Get full text

In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat by Hubner, Richard A, Kubota, Eiji, Casley, David J, Johnston, Colin I, Burrell, Louise M

“…OBJECTIVESVasopeptidase inhibitors are single molecules that simultaneously inhibit neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The…”
Get full text

Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy by Hubner, R.A., Chen, L.-T., Siveke, J.T., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G.S., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J.-F., Chiu, C.-F., Schwartsmann, G., Braiteh, F., Mamlouk, K., Belanger, B., de Jong, F., von Hoff, D.D., Wang-Gillam, A.

Get full text

Re: MLH1 −93G>A Promoter Polymorphism and the Risk of Microsatellite-Unstable Colorectal Cancer by Hubner, Richard A, Houlston, Richard S

Get full text

Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention by HUBNER, Richard A, MUIR, Kenneth R, LIU, Jo-Fen, LOGAN, Richard F. A, GRAINGE, Matthew J, HOULSTON, Richard S

“…Purpose: The chemopreventive activity of aspirin in colorectal neoplasia may be explained in part by its effect on polyamine metabolism. The ornithine…”
Get full text

IN VIVO VASOPEPTIDASE INHIBITION: SIMULTANEOUS INHIBITION OF NEUTRAL ENDOPEPTIDASE AND ANGIOTENSIN CONVERTING ENZYME BY BMS-189921 by Hubner, R. A., Paxton, D., Johnston, C. I., Burrell, L. M.

Get full text

Polymorphisms in PTGS1, PTGS2 and IL‐10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial by Hubner, Richard A., Muir, Kenneth R., Liu, Jo‐Fen, Logan, Richard F.A., Grainge, Matthew J., Houlston, Richard S.

“…Regular use of aspirin and other nonsteroidal antiinflammatory drugs reduces both the development of colorectal neoplasia and recurrence of colorectal adenoma…”
Get full text

Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease by Kubota, E, Dean, R G, Hubner, R A, Balding, L C, Johnston, C I, Burrell, L M

“…In both the natriuretic peptide and renin-angiotensin systems, peptidases play an important role in the inactivation or activation of the system…”
Get full text